← All trials
NCT06992128
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 22, 2025
- Primary completion
- Jan 31, 2028
- Completion date
- Aug 31, 2028
- First posted
- May 28, 2025
- Last posted
- May 28, 2025
- Enrollment
- 129
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- China Academy of Chinese Medical SciencesLead sponsor
- Nantong UniversityCollaborator
- Bengbu Medical CollegeCollaborator
- Dalian Medical UniversityCollaborator
- Qingdao UniversityCollaborator
- China Medical UniversityCollaborator
- Weifang People's HospitalCollaborator
- Changzhi Medical CollegeCollaborator
- North Sichuan Medical UniversityCollaborator
- Baoding First Center HospitalCollaborator
- North China University of Science and Technology Affiliated HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.